Louis P. Garrison Jr, Deborah Lubeck, Deepa Lalla, Virginia Paton, Amylou Dueck and Edith A. Perez Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer Cancer 110
Article first published online: 25 JUN 2007 | DOI: 10.1002/cncr.22806
Adding trastuzumab to adjuvant chemotherapy significantly improves clinical outcomes in patients with HER2-positive early breast cancer. This cost-utility analysis estimates that adjuvant trastuzumab costs $26,417 per quality-adjusted life year gained, from a lifetime, payer perspective, a result that is robust to sensitivity analysis and achieves a cost-effectiveness ratio below that of many widely accepted oncology treatments.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field